Can a cancer drug combo outsmart recurrent brain tumors?

NCT ID NCT03643549

Recruiting now Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial is testing whether adding bortezomib to the standard chemotherapy temozolomide can help people with recurrent glioblastoma, a type of aggressive brain cancer. The study focuses on patients whose tumors have a specific genetic marker (unmethylated MGMT) that often makes them resistant to standard treatment. The goal is to see if the combination is safe and whether it can improve survival and slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bortezomib combined with temozolomide
What this could lead to: If this combination works, it could offer a new treatment option for people with recurrent glioblastoma, potentially extending survival.
What could go wrong: This is an early-phase trial, so the benefits are uncertain. The drug combination may cause side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Haukeland University Hospital
RECRUITING

Bergen, 5021, Norway
Oslo University Hospital
RECRUITING

Oslo, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.